Cannabis Science Inc (OTCMKTS:CBIS) CFO Robert James Kane sold 1,783,475 shares of the stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $0.02, for a total transaction of $35,669.50. Following the completion of the sale, the chief financial officer now directly owns 23,710,717 shares of the company’s stock, valued at $474,214.34. The transaction was disclosed in a filing with the SEC, which is available at this link.

Robert James Kane also recently made the following trade(s):

  • On Tuesday, September 13th, Robert James Kane sold 2,000,000 shares of Cannabis Science stock. The stock was sold at an average price of $0.01, for a total transaction of $20,000.00.

Shares of Cannabis Science Inc (OTCMKTS:CBIS) opened at 0.022 on Friday. The company has a 50-day moving average of $0.02 and a 200 day moving average of $0.02. The stock’s market capitalization is $43.28 million. Cannabis Science Inc has a 12-month low of $0.01 and a 12-month high of $0.03.

Insider Buying and Selling by Quarter for Cannabis Science (OTCMKTS:CBIS)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cannabis Science Company Profile

Cannabis Science, Inc is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Receive News & Ratings for Cannabis Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc and related companies with's FREE daily email newsletter.